Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.

E, Roeseler; U, Julius; F, Heigl; R, Spitthoever; D, Heutling; P, Breitenberger; J, Leebmann; W, Lehmacher; PR, Kamstrup; BG, Nordestgaard; W, Maerz; A, Noureen; K, Schmidt; F, Kronenberg; A, Heibges; R, Klingel

doi:10.1161/atvbaha.116.307983

Public

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.

Shared by NobleBlocks on Jul 14, 2016 • 12:00 AM UTC

Authors:

Roeseler E

Julius U

Heigl F

Abstract

<h4>Objective</h4>Lipoprotein(a)-hyperlipoproteinemia (Lp(a)-HLP) along with progressive cardiovascular disease has been approved as indication for regular lipoprotein apheresis (LA) in Germany since 2008. We aimed to study the long-term preventive effect of LA and to assess hypothetical clinical co...

Subject

Lipoprotein(a)

Cardiovascular disease

Coronary disease

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!